 |
인쇄하기
취소
|
Promising chemotherapy candidate for advanced ovarian cancer may be commercialized, Quest Pharma say
Quest PharmaTech Inc., Canada based pharmaceutical company, is expected to commercialize Oregovomab, a promising chemotherapy candidate for advanced ovarian cancer, according to Quest Pharma.
Oregovomab, a high affinity monoclonal antibody for the treatment of advanced ovarian cancer. Oregovomab targets the circulating tumour associated antigen CA125. The unique mechanism of action of this t...
Oregovomab, a high affinity monoclonal antibody for the treatment of advanced ovarian cancer. Oregovomab targets the circulating tumour associated antigen CA125. The unique mechanism of action of this t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.